La sérotonine pourrait aggraver les symptômes des acouphènes selon une nouvelle étude

De nouvelles recherches montrent que la sérotonine, une substance chimique cérébrale stimulée par de nombreux antidépresseurs, peut intensifier les acouphènes. Les scientifiques ont identifié un circuit cérébral spécifique chez les souris qui relie des niveaux plus élevés de sérotonine à des comportements imitant cette pathologie.

Une équipe de l'Oregon Health & Science University et de l'Université de l'Anhui en Chine a publié ces résultats dans les Proceedings of the National Academy of Sciences. Ils ont utilisé l'optogénétique pour stimuler les neurones producteurs de sérotonine et ont observé une activité accrue dans les régions auditives du cerveau, ainsi que des réponses semblables aux acouphènes chez les souris via un test de sursaut modifié. L'étude s'appuie sur des travaux antérieurs de 2017 et concorde avec les rapports de certains patients dont les acouphènes s'aggravent lors de la prise d'ISRS.

Articles connexes

Lab participants show stress and irritability from inaudible infrasound in a scientific study, with visualized low-frequency waves and cortisol monitors.
Image générée par IA

Study finds infrasound can raise cortisol and irritability even when people can’t hear it

Rapporté par l'IA Image générée par IA Vérifié par des faits

A small controlled experiment reported in Frontiers in Behavioral Neuroscience found that exposure to infrasound—ultra-low-frequency vibration below the range of human hearing—was associated with higher salivary cortisol and more negative mood ratings, even though participants could not reliably detect when the infrasound was present.

Researchers have discovered that psychedelic substances suppress visual processing in the brain, leading to hallucinations by drawing on memory fragments. The study, conducted using advanced imaging on mice, shows how slow brain waves shift perception toward internal recall. These findings could inform therapies for depression and anxiety.

Rapporté par l'IA

A randomized clinical trial found that 24 minutes of specially designed music paired with auditory beat stimulation significantly lowers anxiety symptoms. Researchers at Toronto Metropolitan University tested various listening durations on 144 adults with moderate anxiety. The 24-minute session provided the strongest benefits.

Researchers at UCLA Health report that delivering transcranial magnetic stimulation (TMS) in an intensive five-day schedule—five sessions per day for five days—was associated with depression symptom improvements comparable to a conventional six-week schedule in a retrospective analysis of 175 patients with treatment-resistant depression. The study also found that some patients who showed little immediate change after the accelerated course improved noticeably in the following weeks.

Rapporté par l'IA

A small clinical trial has found that a single dose of the psychedelic drug dimethyltryptamine (DMT) led to rapid and sustained reductions in depression symptoms when combined with therapy. Participants experienced improvements lasting up to six months, with mild side effects reported. The study highlights potential benefits of short-acting psychedelics for treatment-resistant depression.

A study in Molecular Psychiatry used PET imaging with a new tracer to track changes in AMPA-type glutamate receptors in people with treatment-resistant depression receiving ketamine, reporting that region-specific receptor changes were associated with symptom improvement.

Ce site utilise des cookies

Nous utilisons des cookies pour l'analyse afin d'améliorer notre site. Lisez notre politique de confidentialité pour plus d'informations.
Refuser